NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free CRDL Stock Alerts $1.82 +0.06 (+3.41%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.69▼$1.8450-Day Range$1.39▼$2.0652-Week Range$0.55▼$2.17Volume116,022 shsAverage Volume352,608 shsMarket Capitalization$124.27 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Cardiol Therapeutics alerts: Email Address Cardiol Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside229.7% Upside$6.00 Price TargetShort InterestHealthy0.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.25) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector445th out of 908 stocksBiological Products, Except Diagnostic Industry71st out of 153 stocks 3.5 Analyst's Opinion Consensus RatingCardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.42% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiol Therapeutics has recently decreased by 15.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRDL. Previous Next 3.8 News and Social Media Coverage News SentimentCardiol Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cardiol Therapeutics this week, compared to 0 articles on an average week.Search Interest9 people have searched for CRDL on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows10 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.49% of the stock of Cardiol Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cardiol Therapeutics are expected to decrease in the coming year, from ($0.25) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Cardiol Therapeutics Stock (NASDAQ:CRDL)Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.Read More CRDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRDL Stock News HeadlinesApril 25, 2024 | americanbankingnews.comCardiol Therapeutics Inc. (NASDAQ:CRDL) to Post Q1 2024 Earnings of ($0.06) Per Share, HC Wainwright ForecastsApril 23, 2024 | americanbankingnews.comCardiol Therapeutics (NASDAQ:CRDL) Receives New Coverage from Analysts at HC WainwrightApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 20, 2024 | americanbankingnews.comCardiol Therapeutics (NASDAQ:CRDL) Shares Up 6%April 2, 2024 | investorplace.comCRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023April 2, 2024 | proactiveinvestors.comCardiol Therapeutics surpasses enrollment goals, prepares for topline resultsMarch 16, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Friday (CRDL-WT-A)February 22, 2024 | benzinga.comCardiol Therapeutics Stock (NASDAQ:CRDL), Short Interest ReportApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.February 21, 2024 | proactiveinvestors.comCardiol Therapeutics wraps up patient enrollment for Phase II open label studyFebruary 16, 2024 | proactiveinvestors.comCardiol CEO David Elsley unpacks FDA Orphan Drug Designation for CardiolFebruary 15, 2024 | proactiveinvestors.comCardiol Therapeutics receives orphan drug status for its lead drug...February 15, 2024 | theglobeandmail.comOrphan Drug Designation Sends Shares of this Dual-Listed Life Science Therapy Company SoaringFebruary 15, 2024 | msn.comCardiol stock rallies 28% on FDA orphan drug status for CardiolRxFebruary 15, 2024 | proactiveinvestors.comCardiol Therapeutics receives orphan drug status for its lead drug candidateJanuary 9, 2024 | morningstar.comCardiol Therapeutics Inc Class A CRDLJanuary 9, 2024 | finance.yahoo.comCardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute MyocarditisDecember 18, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Tuesday (CRDL-WT-A)November 16, 2023 | finance.yahoo.comCardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesOctober 11, 2023 | finance.yahoo.comCardiol Therapeutics releases positive study results of subcutaneously administered cannabidiolOctober 10, 2023 | proactiveinvestors.comCardiol Therapeutics says study results show positive effects of subcutaneously administered cannabidiolOctober 10, 2023 | finance.yahoo.comCardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection FractionOctober 2, 2023 | benzinga.comCardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)September 27, 2023 | finance.yahoo.comHere's Why You May Invest in Cardiol Therapeutics (CRDL) StockSeptember 19, 2023 | finance.yahoo.comCardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute MyocarditisAugust 26, 2023 | finance.yahoo.comIs Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?August 9, 2023 | finance.yahoo.comCardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth ConferenceSee More Headlines Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CRDL CUSIPN/A CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+229.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.18% Return on Assets-62.52% Debt Debt-to-Equity Ratio0.01 Current Ratio4.36 Quick Ratio4.36 Sales & Book Value Annual Sales$60,000.00 Price / Sales2,071.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book5.69Miscellaneous Outstanding Shares68,280,000Free Float64,699,000Market Cap$124.27 million OptionableNot Optionable Beta0.95 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David G. Elsley MBAPresident, CEO & DirectorMr. Christopher J. Waddick C.A.C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & DirectorMr. Bernard Lim B.Sc.Chief Operating OfficerDr. Andrew Warwick Hamer M.D. (Age 62)Chief Medical Officer & Head of Research & Development Comp: $364.44kTrevor BurnsInvestor RelationsKey CompetitorsOmega TherapeuticsNASDAQ:OMGAVaxartNASDAQ:VXRTAgenusNASDAQ:AGENDBV TechnologiesNASDAQ:DBVTMolecular PartnersNASDAQ:MOLNView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCSold 15,810 shares on 2/14/2024Ownership: 1.821%AXS Investments LLCSold 75,884 shares on 2/9/2024Ownership: 1.068%View All Institutional Transactions CRDL Stock Analysis - Frequently Asked Questions Should I buy or sell Cardiol Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDL shares. View CRDL analyst ratings or view top-rated stocks. What is Cardiol Therapeutics' stock price target for 2024? 3 brokers have issued 12 month target prices for Cardiol Therapeutics' shares. Their CRDL share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 229.7% from the stock's current price. View analysts price targets for CRDL or view top-rated stocks among Wall Street analysts. How have CRDL shares performed in 2024? Cardiol Therapeutics' stock was trading at $0.8432 at the beginning of 2024. Since then, CRDL shares have increased by 115.8% and is now trading at $1.82. View the best growth stocks for 2024 here. Are investors shorting Cardiol Therapeutics? Cardiol Therapeutics saw a decrease in short interest in April. As of April 15th, there was short interest totaling 275,200 shares, a decrease of 15.7% from the March 31st total of 326,600 shares. Based on an average daily trading volume, of 388,300 shares, the short-interest ratio is currently 0.7 days. Approximately 0.4% of the company's stock are sold short. View Cardiol Therapeutics' Short Interest. When is Cardiol Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CRDL earnings forecast. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) issued its quarterly earnings results on Monday, April, 1st. The company reported ($0.09) EPS for the quarter. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRDL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersI’m afraid WWIII is a very real possibility Porter & CompanyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
